Know Cancer

or
forgot password

HLH-2004 Treatment Protocol


Phase 3
N/A
18 Years
Open (Enrolling)
Both
Hemophagocytic Lymphohistiocytosis

Thank you

Trial Information

HLH-2004 Treatment Protocol


The most dangerous period after HLH diagnosis is the first 2 months. In HLH-2004 we provide
additional therapy during this period as compared to in HLH-94.


Inclusion Criteria:



- Patients who fulfil the diagnostic criteria of HLH.

Exclusion Criteria:

- Prior cytotoxic or cyclosporin treatment for HLH.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Survival

Outcome Time Frame:

1-year after diagnosis

Safety Issue:

No

Principal Investigator

Jan-Inge Henter, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Karolinska Institutet

Authority:

Sweden: Regional Ethical Review Board

Study ID:

HLH-2004

NCT ID:

NCT00426101

Start Date:

January 2004

Completion Date:

December 2016

Related Keywords:

  • Hemophagocytic Lymphohistiocytosis
  • Hemophagocytic lymphohistiocytosis
  • Lymphohistiocytosis, Hemophagocytic

Name

Location